FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2773186181> ?p ?o ?g. }

• W2773186181 endingPage "219" @default.
• W2773186181 startingPage "219" @default.
• W2773186181 abstract "Parkinson disease is a progressive neurologic disorder. Limited evidence suggests endurance exercise modifies disease severity, particularly high-intensity exercise.To examine the feasibility and safety of high-intensity treadmill exercise in patients with de novo Parkinson disease who are not taking medication and whether the effect on motor symptoms warrants a phase 3 trial.The Study in Parkinson Disease of Exercise (SPARX) was a phase 2, multicenter randomized clinical trial with 3 groups and masked assessors. Individuals from outpatient and community-based clinics were enrolled from May 1, 2012, through November 30, 2015, with the primary end point at 6 months. Individuals with idiopathic Parkinson disease (Hoehn and Yahr stages 1 or 2) aged 40 to 80 years within 5 years of diagnosis who were not exercising at moderate intensity greater than 3 times per week and not expected to need dopaminergic medication within 6 months participated in this study. A total of 384 volunteers were screened by telephone; 128 were randomly assigned to 1 of 3 groups (high-intensity exercise, moderate-intensity exercise, or control).High-intensity treadmill exercise (4 days per week, 80%-85% maximum heart rate [n = 43]), moderate-intensity treadmill exercise (4 days per week, 60%-65% maximum heart rate [n = 45]), or wait-list control (n = 40) for 6 months.Feasibility measures were adherence to prescribed heart rate and exercise frequency of 3 days per week and safety. The clinical outcome was 6-month change in Unified Parkinson's Disease Rating Scale motor score.A total of 128 patients were included in the study (mean [SD] age, 64 [9] years; age range, 40-80 years; 73 [57.0%] male; and 108 [84.4%] non-Hispanic white). Exercise rates were 2.8 (95% CI, 2.4-3.2) days per week at 80.2% (95% CI, 78.8%-81.7%) maximum heart rate in the high-intensity group and 3.2 (95% CI, 2.8-3.6; P = .13) days per week at 65.9% (95% CI, 64.2%-67.7%) maximum heart rate in the moderate-intensity group (P < .001). The mean change in Unified Parkinson's Disease Rating Scale motor score in the high-intensity group was 0.3 (95% CI, -1.7 to 2.3) compared with 3.2 (95% CI, 1.4 to 5.1) in the usual care group (P = .03). The high-intensity group, but not the moderate-intensity group, reached the predefined nonfutility threshold compared with the control group. Anticipated adverse musculoskeletal events were not severe.High-intensity treadmill exercise may be feasible and prescribed safely for patients with Parkinson disease. An efficacy trial is warranted to determine whether high-intensity treadmill exercise produces meaningful clinical benefits in de novo Parkinson disease.clinicaltrials.gov Identifier: NCT01506479." @default.
• W2773186181 created "2017-12-22" @default.
• W2773186181 creator A5020697442 @default.
• W2773186181 creator A5025359570 @default.
• W2773186181 creator A5033866780 @default.
• W2773186181 creator A5036504452 @default.
• W2773186181 creator A5037492755 @default.
• W2773186181 creator A5041688386 @default.
• W2773186181 creator A5058259509 @default.
• W2773186181 creator A5058321132 @default.
• W2773186181 creator A5062212464 @default.
• W2773186181 creator A5071580456 @default.
• W2773186181 creator A5071591108 @default.
• W2773186181 creator A5071845413 @default.
• W2773186181 creator A5077412275 @default.
• W2773186181 creator A5082171999 @default.
• W2773186181 creator A5089588995 @default.
• W2773186181 date "2018-02-01" @default.
• W2773186181 modified "2023-10-17" @default.
• W2773186181 title "Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease" @default.
• W2773186181 cites W1799639810 @default.
• W2773186181 cites W1920983895 @default.
• W2773186181 cites W1961068767 @default.
• W2773186181 cites W1964386825 @default.
• W2773186181 cites W1976513341 @default.
• W2773186181 cites W1977750438 @default.
• W2773186181 cites W1992237817 @default.
• W2773186181 cites W1999702935 @default.
• W2773186181 cites W2011174050 @default.
• W2773186181 cites W2015085620 @default.
• W2773186181 cites W2056145524 @default.
• W2773186181 cites W2065546153 @default.
• W2773186181 cites W2067848483 @default.
• W2773186181 cites W2086701255 @default.
• W2773186181 cites W2105782494 @default.
• W2773186181 cites W2106350754 @default.
• W2773186181 cites W2110516792 @default.
• W2773186181 cites W2122085123 @default.
• W2773186181 cites W2124612672 @default.
• W2773186181 cites W2124808208 @default.
• W2773186181 cites W2126008330 @default.
• W2773186181 cites W2129106050 @default.
• W2773186181 cites W2140978740 @default.
• W2773186181 cites W2143978324 @default.
• W2773186181 cites W2148747456 @default.
• W2773186181 cites W2150072209 @default.
• W2773186181 cites W2151313540 @default.
• W2773186181 cites W2156606713 @default.
• W2773186181 cites W2159202946 @default.
• W2773186181 cites W2163546233 @default.
• W2773186181 cites W2178282635 @default.
• W2773186181 cites W2262700517 @default.
• W2773186181 cites W2548654048 @default.
• W2773186181 cites W2576845799 @default.
• W2773186181 cites W2593551233 @default.
• W2773186181 cites W2606705525 @default.
• W2773186181 cites W2749718288 @default.
• W2773186181 cites W4211123396 @default.
• W2773186181 doi "https://doi.org/10.1001/jamaneurol.2017.3517" @default.
• W2773186181 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5838616" @default.
• W2773186181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29228079" @default.
• W2773186181 hasPublicationYear "2018" @default.
• W2773186181 type Work @default.
• W2773186181 sameAs 2773186181 @default.
• W2773186181 citedByCount "272" @default.
• W2773186181 countsByYear W27731861812018 @default.
• W2773186181 countsByYear W27731861812019 @default.
• W2773186181 countsByYear W27731861812020 @default.
• W2773186181 countsByYear W27731861812021 @default.
• W2773186181 countsByYear W27731861812022 @default.
• W2773186181 countsByYear W27731861812023 @default.
• W2773186181 crossrefType "journal-article" @default.
• W2773186181 hasAuthorship W2773186181A5020697442 @default.
• W2773186181 hasAuthorship W2773186181A5025359570 @default.
• W2773186181 hasAuthorship W2773186181A5033866780 @default.
• W2773186181 hasAuthorship W2773186181A5036504452 @default.
• W2773186181 hasAuthorship W2773186181A5037492755 @default.
• W2773186181 hasAuthorship W2773186181A5041688386 @default.
• W2773186181 hasAuthorship W2773186181A5058259509 @default.
• W2773186181 hasAuthorship W2773186181A5058321132 @default.
• W2773186181 hasAuthorship W2773186181A5062212464 @default.
• W2773186181 hasAuthorship W2773186181A5071580456 @default.
• W2773186181 hasAuthorship W2773186181A5071591108 @default.
• W2773186181 hasAuthorship W2773186181A5071845413 @default.
• W2773186181 hasAuthorship W2773186181A5077412275 @default.
• W2773186181 hasAuthorship W2773186181A5082171999 @default.
• W2773186181 hasAuthorship W2773186181A5089588995 @default.
• W2773186181 hasBestOaLocation W27731861811 @default.
• W2773186181 hasConcept C121332964 @default.
• W2773186181 hasConcept C126322002 @default.
• W2773186181 hasConcept C1862650 @default.
• W2773186181 hasConcept C2776811442 @default.
• W2773186181 hasConcept C2777953023 @default.
• W2773186181 hasConcept C2779134260 @default.
• W2773186181 hasConcept C2779734285 @default.
• W2773186181 hasConcept C62520636 @default.
• W2773186181 hasConcept C71924100 @default.
• W2773186181 hasConcept C84393581 @default.

• next